Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019

Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019

Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Satoshi Ide, Sho Saito, Tsubasa Akazawa, Takahito Furuya, Junichi Masuda, Maki Nagashima, Yusuke Asai, Tatsunori Ogawa, Ryohei Yamamoto, Haruhiko Ishioka, Kohei Kanda, Ayako Okuhama, Yuji Wakimoto, Tetsuya Suzuki, Yutaro Akiyama, Yusuke Miyazato, Keiji Nakamura, Takato Nakamoto, Hidetoshi Nomoto, Yuki Moriyama, Masayuki Ota, Shinichiro Morioka, Wataru Matsuda, Tatsuki Uemura, Kentaro Kobayashi, Ryo Sasaki, Daisuke Katagiri, Satoshi Kutsuna, Kayoko Hayakawa, Norio Ohmagari
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Remdesivir
Severe COVID-19
Extracorporeal membrane oxygenation
Pharmacokinetics analysis
Infectious and parasitic diseases
RC109-216
Accès en ligne:https://doaj.org/article/460b8a8db4254010b8c675bebb5d2ae4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/460b8a8db4254010b8c675bebb5d2ae4

Documents similaires